Intelligence Profile
Clinical Applications
Cerebrolysin is primarily investigated for neurological conditions, with stroke recovery being the most extensively studied application. The available evidence suggests several clinical uses, though the quality and scope of evidence varies significantly.
Primary Clinical Applications
Stroke Recovery
Multiple clinical trials have examined Cerebrolysin's role in stroke treatment. A completed Phase 4 trial (NCT01996761) specifically evaluated its effects on motor recovery in subacute stroke patients. Additionally, a 2026 systematic review and meta-analysis examined Cerebrolysin as an adjunct to mechanical thrombectomy in acute ischemic stroke, analyzing observational studies for both efficacy and safety outcomes. A broader comparative effectiveness study (NCT01556854) investigated neuroprotectants including Cerebrolysin for acute ischemic stroke, though the status of this trial remains unknown.
Traumatic Brain Injury
A 6-month prospective cohort study published in 2026 analyzed Cerebrolysin's neuroprotective effects in moderate traumatic brain injury patients with nonoperative lesions, suggesting potential therapeutic benefits in this population.
Emerging Clinical Areas
Bell's Palsy
An ongoing Phase 1/2 trial (NCT05821075) is comparing Cerebrolysin's efficacy against prednisolone for Bell's palsy treatment, indicating interest in its application for peripheral facial nerve disorders.
COVID-19-Related Sensory Loss
A completed Phase 4 trial (NCT06208540) investigated Cerebrolysin for treating anosmia and ageusia caused by SARS-CoV-2 variants, representing a novel application area.
Post-Stroke Aphasia
A 2026 review examined therapy prospects for post-stroke aphasia, though specific details about Cerebrolysin's role are not available from the provided evidence.
Mechanistic Research
Laboratory studies suggest Cerebrolysin may work through multiple pathways. Research from 2026 showed that exosomes released by Cerebrolysin-treated cerebral endothelial cells could reverse certain types of endothelial barrier dysfunction, potentially explaining some of its therapeutic effects in cerebrovascular conditions.
Limitations and Considerations
The evidence base contains several retracted studies, indicating some previously reported findings may not be reliable. Additionally, one unusual completed trial (NCT05288465) investigated hair repigmentation during Cerebrolysin therapy, though the clinical significance of this observation is unclear.
This information is for educational purposes only and should not replace professional medical advice. Patients should consult with their healthcare providers about appropriate treatment options.